Specific Biologics Welcomes Paul J. Hastings as Chair of the Board of Directors
TORONTO, June 11, 2025 /PRNewswire/ - Specific Biologics Inc., a biotechnology company advancing Dualase® genome editors for precise and programmable in vivo genome editing, today announced the appointment of Paul J. Hastings as Chair of its Board of Directors.
Mr. Hastings is a distinguished leader in the biopharmaceutical industry and currently serves as Chief Executive Officer and Board Member of engineered cell therapy company Nkarta since 2018. He is also a current Director of EnGene, a non-viral gene therapy company, and recently served as the Chair of the Biotechnology Innovation Organization (BIO). Over his career, he has held numerous top leadership roles, including CEO of OncoMed, QLT, Axys Pharmaceuticals, and LXR Biotechnology, and President of Chiron BioPharmaceuticals. He has guided corporate strategy as Chair of Pacira Biosciences, Proteon Therapeutics and Proteolix, and as a Director of ViaCyte, Relypsa and ViaCell, and previously held leadership roles in global biotechnology companies as President of Genzyme Therapeutics Europe and Genzyme Global Therapeutics, as well as progressive executive roles at Hoffmann-La Roche. A committed mentor and patient advocate, he co-founded and chairs the board of Youth Rally Inc. and serves on the Board of the Termeer Foundation.
"I am thrilled to welcome Paul to the Board," said Brent Stead, CEO of Specific Biologics. "His proven ability to lead and scale high-impact biotechnology companies with breakthrough technologies will be instrumental as we advance our Dualase® platform toward the clinic for patients in need. We are entering an exciting new phase of growth, and Paul's leadership of the Board will be invaluable."
"I'm honored to join the Board of Specific Biologics at such a pivotal time," said Hastings. "The Dualase® technology has the potential to reshape how we approach treating some of the most challenging genetic diseases. I look forward to working with the leadership team and Board to support Specific's mission and drive meaningful impact for patients with limited therapeutic options."
Specific Biologics also extends its sincere gratitude to Dr. Steven Kanner for his dedicated service on the Board and guidance during a critical phase of the company's development. "Steve played a key role in helping shape our early strategy and set the foundation for our current momentum," said Stead.
About Specific Biologics Inc.
Specific Biologics is a venture-backed biotechnology company developing Dualase®, an industry-leading genome editing platform for precise, efficient, and programmable in vivo genome editing, with an initial therapeutic focus on the precise collapse of pathogenic repeat expansions in neurodegenerative disease. Its unique two-site mechanism enables the seamless removal, repair, or insertion of both small and large DNA sequences, offering broad therapeutic potential, coupled with single AAV or all-RNA delivery. Dualase® achieves best-in-class accurate editing efficiency with undetectable off-target effects as demonstrated in preclinical cell and animal models at diverse targets and indications.
For more information, visit www.specificbiologics.com or follow Specific Biologics Inc. on LinkedIn at https://www.linkedin.com/company/specific-biologics
View original content to download multimedia:https://www.prnewswire.com/news-releases/specific-biologics-welcomes-paul-j-hastings-as-chair-of-the-board-of-directors-302478969.html
SOURCE Specific Biologics Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
17 minutes ago
- USA Today
Think Power Solutions Earns Great Place to Work(R) Certification for Fifth Consecutive Year
AI Innovation, Entrepreneurial Culture, M&A Growth, and Operational Excellence Fuel 2025 Recognition Think Power Solutions , a leading provider of AI-enabled utility infrastructure solutions, proudly announces its fifth consecutive Great Place to Work® Certification™ , highlighting its exemplary commitment to fostering a safe, entrepreneurial, and empowering work environment. 'This recognition, for the fifth consecutive year, is especially meaningful because it's based entirely on feedback from our teams,' said Hari Vasudevan, PE, Founder & CEO of Think Power Solutions. 'At Think Power, we believe that when we take care of our people, they care for our customers and investors. As we continue to grow both organically and through targeted acquisitions, we remain focused on driving AI-powered innovation, strengthening customer relationships, and fostering a workplace culture that sets the standard for safety and excellence in the utility industry.' Driving Organic Growth and M&A Strategy As part of its long-term strategy, Think Power Solutions continues to seek partnerships with entrepreneur/family-led firms specializing in utility infrastructure services that drive America's electric utility resilience, reliability, and smarter capital investment. Focus areas include: Advisory services Engineering services Project management Specialized field services Software solutions Through strategic M&A, the company aims to scale nationally, generate operational synergies, and accelerate industry-wide AI innovation to better serve its clients. 'We couldn't be prouder of the positive response we received from our employees. This is a testament to our employee-centric culture that binds us together. We're excited to drive further growth in the utility sector and will continue to improve our workplace culture. Think Power Solutions continues to attract top talent and deliver industry-leading utility infrastructure services,' said David Chandler , CHRO, Think Power Solutions. Think Power fosters a culture where employees are empowered, connected, and driven by purpose. This commitment is reflected in key survey results: nearly 90% of employees express strong pride in their work and believe customers would rate Think Power's service as 'excellent.' These insights reinforce the company's people-first philosophy and reputation for delivering high-performance, client-focused solutions. About Think Power Solutions Think Power Solutions is a leading provider of AI-enabled utility infrastructure solutions. The company partners with many of the nation's largest investor-owned and cooperative utilities. Known for its operational excellence, innovative technology, and industry-leading safety record, Think Power has earned a reputation as a trusted partner in the utility sector. The company actively engages in key industry organizations, including the Edison Electric Institute (EEI), and maintains a strong client-focused approach. With a culture rooted in innovation, excellence, and employee engagement, Think Power continues to attract top-tier talent and deliver solutions that support the evolving needs of the utility industry. Learn more at . Follow us on LinkedIn , Twitter , and Facebook . About Great Place To Work® As the global authority on workplace culture, Great Place To Work® brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Their proprietary platform and For All™ Model helps companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified™ or receiving recognition on a coveted Best Workplaces™ List. Media Contact: Sayantan Dasgupta Director, Marketing – Brand & Content SOURCE: Think Power Solutions View the original press release on ACCESS Newswire
Yahoo
21 minutes ago
- Yahoo
Xediton Pharmaceuticals Inc. ("Xediton") Announced Today the Canadian Approval and Availability of Vabomere(r) (Meropenem-Vaborbactam) in Canada
Oakville, Ontario--(Newsfile Corp. - June 12, 2025) - Xediton Pharmaceuticals Inc. is proud to announce that Vabomere® (meropenem-vaborbactam) has been approved by Health Canada and is now commercially available across the country. Vabomere is indicated in adults for the treatment of complicated urinary tract infections including pyelonephritis, complicated intra-abdominal infection, hospital acquired pneumonia including ventilator associated pneumonia, bacteremia and other infections with limited treatment options known or suspected to be caused by susceptible microorganisms, including KPC-producing CRE—one of the most critical AMR threats identified by Health Canada and the World Health Organization. "The launch of Vabomere® in Canada marks a significant milestone for our company, patients and healthcare practitioners," said George Gafrey, President of Xediton Pharmaceuticals. This therapy provides physicians with a much-needed tool to treat life-threatening infections caused by organisms that are increasingly difficult to manage. We are proud of the collaborative effort by the Melinta and Xediton teams to make the product available, and we are committed to ensuring it reaches those who need it most." "We are thrilled that VABOMERE is now readily accessible to patients in Canada," said Christine Ann Miller, President and Chief Executive Officer at Melinta. We are pleased to be able to partner with Xediton Pharmaceuticals in support of the registration and commercializing of VABOMERE in Canada, continuing to deliver on Melinta's commitment of ensuring that all people who need our life-saving therapies can get them." Vabomere combines meropenem, a trusted broad-spectrum carbapenem, with vaborbactam, a novel β-lactamase inhibitor. The approval is supported by data from TANGO II, a global Phase III clinical trial demonstrating improved clinical cure rates and survival compared to best available therapy in patients with CRE infections. Vabomere reflects Xediton Pharma's commitment to supporting antimicrobial stewardship and advancing therapies that protect patients and preserve the power of antibiotics. About Vabomere® VABOMERE is an antibacterial combination product for intravenous infusion containing meropenem (a trusted carbapenem) and vaborbactam (a novel beta-lactamase inhibitor). VABOMERE is indicated in adults for the treatment of the following infections known or suspected to be caused by carbapenem-resistant, vaborbactam/meropenem-susceptible Gram-negative bacteria: Complicated urinary tract infections (cUTI), including pyelonephritis, Complicated intra-abdominal infection (cIAI), Hospital acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), Bacteremia that occurs in association with, or is suspected to be associated with, any of the infections listed above, Other infections with limited treatment options. Gram-negative organisms include Enterobacterales, such as Enterobacter cloacae, Escherichia coli, and Klebsiella pneumoniae. To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. For further information on VABOMERE, please consult the product monograph available at: About Xediton Pharmaceuticals Inc. Xediton Pharmaceuticals is a specialty pharmaceutical company with a focus on meeting the needs of patients, physicians and partners. Xediton Pharmaceuticals is committed to developing, partnering and making available new and established medicines to promote the health of Canadians. Located in the Greater Toronto Area, Canada, Xediton Pharmaceuticals has products in Oncology, Anti-Infectives, Pain, CNS, GI, Ophthalmology, Renal and CV and has built strong strategic alliances with Global and International Healthcare and pharmaceutical companies. For more information, please visit About Melinta TherapeuticsMelinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. The company focuses its expanding portfolio on serving patients with an unmet need because that's how it makes the most meaningful impact. Melinta Therapeutics' portfolio currently includes seven commercial-stage products: BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), MINOCIN® (minocycline) for Injection, ORBACTIV® (oritavancin), REZZAYO® (rezafungin for injection), TOPROL-XL® (metoprolol succinate) and VABOMERE® (meropenem and vaborbactam). For more information about Melinta Therapeutics, its commitment to patients, and its portfolio of therapies, including their important safety information, visit Contact:George Gafrey, President of Xediton Pharmaceuticals info@ To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Norfolk Southern board of directors elects Richard Anderson as chair
ATLANTA, June 12, 2025 /PRNewswire/ -- Norfolk Southern Corporation's (NYSE: NSC) Board of Directors has unanimously appointed Richard H. Anderson, the former CEO and Executive Chairman of Delta Air Lines, President of Optum Health, CEO of Northwest Airlines, and most recently President and CEO of Amtrak, as the independent chair of the board, effective immediately. Anderson has served on Norfolk Southern's board since May of 2024. Anderson will also serve as chair of the Executive Committee and the Strategy & Planning Committee. In addition, Jack Huffard, co-founder and director of Tenable Holdings, Inc., has been appointed as chair of the Compensation and Talent Management Committee. These appointments are also effective immediately. The board has agreed to reduce its size to 12 members and remaining committee chairs will continue in their existing positions. "Since the very beginning of his time on our board, Richard has contributed deep, experience-based business insight and a collaborative style that has helped drive cohesion among the newly-constituted Board," said Mark George, President and CEO of Norfolk Southern. "I look forward to working with him in this new capacity as we continue to build on Norfolk Southern's strong momentum, advance our strategic priorities, and deliver long-term value for our shareholders, customers, and employees." Anderson said, "During my year on the board, I've seen firsthand how the Norfolk Southern team has propelled the company forward — delivering strong performance for stakeholders and becoming an even safer, more efficient railroad. Alongside the management team and dedicated employees, the board remains focused on delivering value for all our stakeholders." More about Richard H. Anderson is available at About Norfolk Southern Since 1827, Norfolk Southern Corporation (NYSE: NSC) and its predecessor companies have safely moved the goods and materials that drive the U.S. economy. Today, it operates a 22-state freight transportation network. Committed to furthering sustainability, Norfolk Southern helps its customers avoid approximately 15 million tons of yearly carbon emissions by shipping via rail. Its dedicated team members deliver approximately 7 million carloads annually, from agriculture to consumer goods. Norfolk Southern also has the most extensive intermodal network in the eastern U.S. It serves a majority of the country's population and manufacturing base, with connections to every major container port on the Atlantic coast as well as major ports across the Gulf Coast and Great Lakes. Learn more by visiting View original content to download multimedia: SOURCE Norfolk Southern Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
